Interferon is another type of immunotherapy. Bone marrow cells and some white blood cells release this hormone-like substance. When it's used as a drug, it can slow the growth of myeloma cells. You might take interferon if you've had treatment and are in remission, which means your doctor...
Multiple myeloma, malignant proliferation of cells within the bone marrow that usually occurs during middle age or later and increases in occurrence with age. Myelomas are slightly more common in males than in females and can affect any of the marrow-con
Multiple myelomaQuality of lifeMultiple myeloma is a bone marrow neoplasia with an incidence of 6/100,000/year in Europe. While the disease remains incurable, the development of novel treatments such as autologous stem cell transplantation, proteasome inhibitors and monoclonal antibodies has led to ...
Multiple Myeloma Bone Disease - ScienceDirectEvangelos TerposMaria GavriatopoulouEncyclopedia of Endocrine Diseases (Second Edition)
Myeloma destroys the bone by making osteoclasts – cells that break down old bones – become more active and weaken your bones. At the same time, myeloma cells slow down the activity of osteoblasts – cells that lay down new bone. These soft spots are calledlytic lesions. Increased bone brea...
In order to clarify the mechanisms involved in the occurrence of lytic bone lesions (BL) in multiple myeloma (MM), we have compared the presenting myeloma-induced histological bone changes of 14 previously untreated MM patients with lytic BL with those of seven MM patients lacking lytic BL at ...
Bone disease in Multiple Myeloma 来自 scientificcircle.com 喜欢 0 阅读量: 21 作者: VTM Hungria 摘要: The major clinical manifestation of multiple myeloma is related to osteolytic bone destruction. Bone disease can lead to pathologic fractures, spinal cord compression, hypercalcemia, and pain, and...
Multiple myeloma is a plasma cell dyscrasia that frequently involves the bone marrow of the spine. These tumors are typically chemosensitive and radiation sensitive. Multiple myeloma promotes osteoclast activation and osteoblast inhibition, resulting in osteolysis of the vertebral bodies and subsequent co...
Multiple myeloma (MM) is an osteolytic malignancy that is incurable due to the emergence of treatment resistant disease. Defining how, when and where myeloma cell intrinsic and extrinsic bone microenvironmental mechanisms cause relapse is challenging with current biological approaches. Here, we report ...
THERE that the typical and characteristic lesion of bone in multiple myeloma is a discrete osteolytic involvement. The roentgenographic appearance is